ClinicalTrials.gg

Program

PA032

A development code. Also written as “Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)”.

Its studies are led by Hangzhou Yirui Pharmaceutical Technology.

Furthest: phase 1, since Nov 20, 20253 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Yirui Pharmaceutical Technology33 open or runningphase 1since Nov 20, 2025Nov 20, 2025Sep 30, 2027phase 1 · NCT07285967

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2025First study: phase 1 study in SafetyFirst studyNCT07285967 · 64 planned
  2. Jun 22, 2026Phase 1 study in Health Adult SubjectsNCT07673458 · 18 planned · China
  3. Oct 9, 2026Phase 1 study in SafetyNCT07878481 · 64 planned

Ahead

  1. Sep 30, 2027Primary completion: phase 1 study in SafetyNCT07285967
  2. Oct 30, 2027Primary completion: phase 1 study in SafetyNCT07878481

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07878481Safety1Not yet recruitingOct 30, 202764
NCT07673458Health Adult Subjects · China1RecruitingSep 18, 202618
NCT07285967Safety1Not yet recruitingSep 30, 202764

How it is read

Names in the registry

  • “Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)”, 2 entries
  • “PA032”, 1 entry

Codes read as this program: PA032.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.